Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1989 1
1991 1
1992 1
1995 2
1996 4
1997 3
1998 4
1999 1
2000 2
2002 1
2003 3
2004 1
2005 3
2006 4
2007 1
2008 1
2010 3
2011 3
2012 5
2013 3
2014 8
2015 6
2016 8
2017 7
2018 2
2019 14
2020 14
2021 10
2022 7
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
You R, Liu YP, Huang PY, Zou X, Sun R, He YX, Wu YS, Shen GP, Zhang HD, Duan CY, Tan SH, Cao JY, Li JB, Xie YL, Zhang YN, Wang ZQ, Yang Q, Lin M, Jiang R, Zhang MX, Hua YJ, Tang LQ, Zhuang AH, Chen QY, Guo L, Mo HY, Chen Y, Mai HQ, Ling L, Liu Q, Chua MLK, Chen MY. You R, et al. JAMA Oncol. 2020 Sep 1;6(9):1345-1352. doi: 10.1001/jamaoncol.2020.1808. JAMA Oncol. 2020. PMID: 32701129 Free PMC article. Clinical Trial.
IMPORTANCE: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. OBJECTIVE: To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. ...
IMPORTANCE: The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) i …
Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.
Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J. Mao YP, et al. BMJ. 2023 Feb 6;380:e072133. doi: 10.1136/bmj-2022-072133. BMJ. 2023. PMID: 36746459 Free PMC article. Clinical Trial.
PARTICIPANTS: Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement. INTERVENTIONS: Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer …
PARTICIPANTS: Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma …
First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis.
Han J, Zeng N, Tian K, Liu Z, She L, Wang Z, He J, Chen N. Han J, et al. Head Neck. 2023 Sep;45(9):2246-2258. doi: 10.1002/hed.27452. Epub 2023 Jul 12. Head Neck. 2023. PMID: 37435624
OBJECTIVES: Recently updated results of randomized clinical trials (RCTs) have confirmed that toripalimab, camrelizumab, and tislelizumab plus chemotherapy (TOGP, CAGP, and TIGP) significantly prolonged survival compared to placebo plus chemotherapy (PLGP) in the first-line treat …
OBJECTIVES: Recently updated results of randomized clinical trials (RCTs) have confirmed that toripalimab, camrelizumab, and tislelizumab pl …
Metastatic Patterns and Prognosis of de novo Metastatic Nasopharyngeal Carcinoma in the United States.
Xu Y, Huang T, Mao M, Zhai J, Chen J. Xu Y, et al. Laryngoscope. 2021 Apr;131(4):E1130-E1138. doi: 10.1002/lary.28983. Epub 2020 Aug 24. Laryngoscope. 2021. PMID: 32833262
OBJECTIVE: To evaluate the distant metastatic patterns and prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in de novo metastatic nasopharyngeal carcinoma (mNPC) using the Surveillance, Epidemiology, and End Results (SEER) datab …
OBJECTIVE: To evaluate the distant metastatic patterns and prognostic factors for overall survival (OS) and cancer-specific survival (CSS) i …
Advances in nasopharyngeal carcinoma.
Guigay J. Guigay J. Curr Opin Oncol. 2008 May;20(3):264-9. doi: 10.1097/CCO.0b013e3282fad846. Curr Opin Oncol. 2008. PMID: 18391624 Review.
Previous publications have shown that induction chemotherapy with new agents might be promising. Data demonstrating targeted therapies efficacy in metastatic nasopharyngeal carcinoma are limited to date. SUMMARY: Positron emission tomography-computed tomograp …
Previous publications have shown that induction chemotherapy with new agents might be promising. Data demonstrating targeted therapies effic …
Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.
Mao YP, Tang LL, Chen L, Sun Y, Qi ZY, Zhou GQ, Liu LZ, Li L, Lin AH, Ma J. Mao YP, et al. Chin J Cancer. 2016 Dec 28;35(1):103. doi: 10.1186/s40880-016-0167-2. Chin J Cancer. 2016. PMID: 28031050 Free PMC article.
This study aimed to identify the prognostic factors and failure patterns of non-metastatic nasopharyngeal carcinoma (NPC) in the intensity-modulated radiotherapy (IMRT) era. ...
This study aimed to identify the prognostic factors and failure patterns of non-metastatic nasopharyngeal carcinoma (NP …
127 results